LANGHORNE, Pa. / Nov 20, 2025 / Business Wire / Savara Inc. (Nasdaq: SVRA) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced members of the management team will host one on one meetings and participate in fireside chats at two upcoming healthcare conferences. Fireside Chats: Piper Sandler 37 th Annual Healthcare Conference December 2, 2025, 2:30pm ET Evercore... Read More

On Track to Resubmit the Biologics License Application (BLA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) in December and Will Request Priority Review Expect to Submit the MOLBREEVI Marketing Authorization Applications (MAA) for Autoimmune PAP to the European Medicines Agency (EMA) and the UK Medicines and Healthcare Products Regulatory Agency (MHRA) in 1Q 2026 Recently Strengthened Balance... Read More

LANGHORNE, Pa. / Nov 03, 2025 / Business Wire / Savara Inc. (Nasdaq: SVRA) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced members of the management team will host 1x1 meetings and participate in fireside chats at two upcoming healthcare conferences. Fireside Chats: Guggenheim 2 nd Annual Healthcare Innovation Conference November 10, 2025, 8:30 a.m. ET... Read More

LANGHORNE, Pa. / Oct 31, 2025 / Business Wire / Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the closing of its previously announced underwritten public offering of 28,452,381 shares of common stock, including 4,642,857 shares of common stock sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares,... Read More

LANGHORNE, Pa. / Oct 29, 2025 / Business Wire / Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the pricing of an underwritten public offering of 23,809,524 shares of its common stock at a price of $4.20 per share and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase 7,142,857 shares of common stock at a... Read More

LANGHORNE, Pa. / Oct 29, 2025 / Business Wire / Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. The proposed offering is subject to market and... Read More

RTW Committed $75M in Launch Funding, Subject to U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI Royalties Based on Annual Net Sales of MOLBREEVI in the U.S. Funds Will Strengthen the Company’s Balance Sheet for Potential U.S. Commercialization of MOLBREEVI in Autoimmune PAP LANGHORNE, Pa. / Oct 29, 2025 / Business Wire / Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company... Read More

Yasmine Wasfi, M.D., Ph.D., FCCP Promoted to CMO, Effective Immediately CMO Ray Pratt, M.D., FACP to Transition to Senior Medical Advisor LANGHORNE, Pa. / Oct 17, 2025 / Business Wire / Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced Yasmine Wasfi, M.D., Ph.D., FCCP has been promoted to CMO, effective immediately. She succeeds Ray... Read More

Savara’s Partner, TrilliumBiO, to Present Encore Data on the Development of a Dried Blood Spot Test to Aid in the Diagnosis of aPAP LANGHORNE, Pa. / Oct 02, 2025 / Business Wire / Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of two abstracts for poster presentation and one abstract as an oral presentation at CHEST... Read More

The Beneficial Clinical Effects of Molgramostim Were Similar in Patients with aPAP Regardless of Disease Severity Defined by DLco% Changes in DLco%, the Primary Endpoint in IMPALA-2, Were Significantly Correlated with Changes in Measures of Quality of Life, Patient Functionality, and Surfactant Burden in Patients with aPAP Savara’s Partner, TrilliumBiO, Presented Data on the Development of a Dried Blood Spot Test to Aid in... Read More

Approximately 5,500 Autoimmune PAP Patients in the U.S. Identified in the Updated Analysis that Leveraged a More Recent and Comprehensive Claims Data Source New England Journal of Medicine (NEJM) Recently Published Results from Savara’s Pivotal Phase 3 IMPALA-2 Clinical Trial of MOLBREEVI* in Autoimmune PAP On Track to Resubmit Biologics License Application (BLA) in December 2025 for MOLBREEVI in Autoimmune PAP, Will Request... Read More

LANGHORNE, Pa. / Aug 26, 2025 / Business Wire / Savara Inc. (Nasdaq: SVRA) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced members of the management team will host 1x1 meetings and present at two upcoming healthcare conferences. Wells Fargo Securities Healthcare Conference September 3, 2025, 4:30pm ET/1:30pm PT H.C. Wainwright Global Healthcare Conference... Read More

In the Largest Clinical Trial Conducted in Autoimmune PAP, Molgramostim Inhalation Solution (Molgramostim) Reduced Surfactant Burden and Improved Pulmonary Gas Transfer, Respiratory Health-Related Quality of Life, and Patient Functionality LANGHORNE, Pa. / Aug 20, 2025 / Business Wire / Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that... Read More

Savara’s Partner, TrilliumBiO, to Present Data on the Development of a Dried Blood Spot Test to Aid in the Diagnosis of aPAP LANGHORNE, Pa. / Aug 18, 2025 / Business Wire / Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of three abstracts for poster presentation at the European Respiratory Society (ERS) Congress 2025,... Read More

Reached Alignment with the U.S. Food and Drug Administration (FDA) on Information Needed for Resubmission of the Biologics License Application (BLA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) Plan to Resubmit the BLA in December with FUJIFILM Biotechnologies (Fujifilm) as the Drug Substance Manufacturer and Will Request Priority Review Anticipate Submitting the MOLBREEVI... Read More

LANGHORNE, Pa. / Jul 18, 2025 / Business Wire / Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees. On July 15, 2025, the Compensation Committee of Savara's Board of Directors granted the inducement awards to two new employees who recently joined the Company. The inducement awards consist of options... Read More

LANGHORNE, Pa. / May 27, 2025 / Business Wire / Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced that the Company received an RTF letter from the FDA for the BLA of MOLBREEVI as a therapy to treat patients with autoimmune PAP. Upon preliminary review, the FDA determined that the BLA submitted in March 2025 was not sufficiently complete... Read More

LANGHORNE, Pa. / May 23, 2025 / Business Wire / Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to five new employees. On May 21, 2025, the Compensation Committee of Savara's Board of Directors granted the inducement awards to five new employees who recently joined the Company. The inducement awards consist of options... Read More

LANGHORNE, Pa. / May 22, 2025 / Business Wire / Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced members of the management team will host 1x1 meetings and present at the Jefferies Global Healthcare Conference on June 4, 2025, at 9:20am ET/6:20am PT. The live webcast and subsequent replay will be available on the “Events & Presentations”... Read More

LANGHORNE, Pa. / May 18, 2025 / Business Wire / Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced new data in two poster presentations at the ATS International Conference 2025. Data presented were from the Phase 3 IMPALA-2 clinical trial of molgramostim in aPAP and demonstrated that molgramostim reduces surfactant burden and improves... Read More

Completed Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI * as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) and Requested Priority Review Company Remains on Track to Submit the MOLBREEVI Marketing Authorization Application (MAA) for Autoimmune PAP to the European Medicines Agency (EMA) and the Medicines and Healthcare Products... Read More

LANGHORNE, Pa. / May 12, 2025 / Business Wire / Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced members of the management team will host 1x1 meetings and present at the H.C. Wainwright & Co. 3 rd Annual BioConnect Investor Conference on May 20, 2025, at 4:30pm ET/1:30pm PT. The live webcast and subsequent replay will be available on... Read More

LANGHORNE, Pa. / May 01, 2025 / Business Wire / Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team will be hosting 1x1 meetings and participating in a fireside chat at the Citizens Life Sciences Conference on Thursday, May 8, 2025 at 10:30am EST/7:30am PST. The live webcast and subsequent replay will be... Read More

LANGHORNE, Pa. / Apr 11, 2025 / Business Wire / Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to seven new employees. On April 9, 2025, the Compensation Committee of Savara's Board of Directors granted the inducement awards to seven new employees who recently joined the Company. The inducement awards consist of... Read More

LANGHORNE, Pa. / Apr 07, 2025 / Business Wire / Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, announced encore presentations of top-line data from the pivotal, Phase 3 IMPALA-2 clinical trial of molgramostim in aPAP will be presented at the 65 th Congress of the German Society of Pneumology (DGP) in Leipzig, Germany taking place April 9-12 and at... Read More

Completed Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI * as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Priority Review Was Requested, Commercial Launch Preparations Underway With ~$196M in Cash and Short-Term Investments as of December 31, 2024, the Company Believes it is Sufficiently Capitalized through 2Q 2027, Excluding the Recent... Read More

Includes $30M at Close to Refinance Existing Debt Facility LANGHORNE, Pa. / Mar 26, 2025 / Business Wire / Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has entered into a loan and security agreement with Hercules Capital, Inc. (NYSE: HTGC), for up to $200 million. Access to the additional capital strengthens Savara’s balance... Read More

Priority Review Was Requested, Commercial Launch Preparations Underway MOLBREEVI Has the Potential to Be the First and Only Approved Therapy for aPAP in the U.S. and Europe Company Remains on Track to Submit the Marketing Authorization Application (MAA) in Europe by the End of 2025 LANGHORNE, Pa. / Mar 26, 2025 / Business Wire / Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on... Read More

Company to Host Industry Theater on aPAP with Two World-Renowned Experts LANGHORNE, Pa. / Mar 17, 2025 / Business Wire / Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of two abstracts for poster presentation at the American Thoracic Society (ATS) International Conference taking place May 16-21, 2025, in San Francisco,... Read More

The Simple, No-cost Test Can Detect Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Autoantibodies in the Blood with Only a Finger Prick LANGHORNE, Pa. / Mar 06, 2025 / Business Wire / Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the launch of the aPAP ClearPath Dried Blood Spot (DBS) Test in the U.S., an evolution of the first... Read More

LANGHORNE, Pa. / Mar 03, 2025 / Business Wire / Savara Inc . (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of its management team will attend the Leerink Global Healthcare Conference and participate in a fireside chat on Tuesday, March 11 th , 10:40am ET/7:40am PT. The live webcast and subsequent replay will be available on the... Read More

LANGHORNE, Pa. / Feb 14, 2025 / Business Wire / Savara Inc . (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to five new employees. On February 12, 2025, the Compensation Committee of Savara's Board of Directors granted the inducement awards to five new employees who recently joined the Company. The inducement awards consist of... Read More

Real World, Retrospective Outcomes Data Suggest Molgramostim Addresses the Underlying Pathophysiology of aPAP Resulting in Improved Lung Function, Decreased Disease Burden, Restored Patient Functionality, and Reduction of Clinical Symptoms LANGHORNE, Pa. / Jan 30, 2025 / Business Wire / Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced a... Read More

LANGHORNE, Pa. / Jan 29, 2025 / Business Wire / Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of its management team will be attending two upcoming healthcare investor conferences and participating in fireside chats at each. Guggenheim SMID Cap Biotech Conference, February 5-6, 2025 Fireside Chat: February 5 th , 10:00am... Read More

LANGHORNE, Pa. / Dec 23, 2024 / Business Wire / Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to five new employees. On December 20, 2024, the Compensation Committee of Savara's Board of Directors granted the inducement awards to five new employees who recently joined the Company. The inducement awards consist of... Read More

Company Expects to Complete BLA Submission by End of 1Q 2025 LANGHORNE, Pa. / Dec 18, 2024 / Business Wire / Savara Inc. (Nasdaq: SVRA ) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, initiated a rolling submission of a BLA to the FDA for MOLBREEVI for the potential treatment of aPAP, a chronic and debilitating rare lung disease characterized by the abnormal build-up of... Read More

LANGHORNE, Pa. / Dec 17, 2024 / Business Wire / Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the Company will present and host 1x1 meetings at the 43 rd Annual J.P. Morgan Healthcare Conference. Date/Time of Presentation: January 15, 5:15pm PT/8:15pm ET Presenter: Matt Pauls, Chair and Chief Executive Officer, Savara Location:... Read More

LANGHORNE, Pa. / Nov 22, 2024 / Business Wire / Savara Inc . (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to four new employees. On November 20, 2024, the Compensation Committee of Savara's Board of Directors granted the inducement awards to four new employees who recently joined the Company. The inducement awards consist of... Read More

LANGHORNE, Pa. / Nov 22, 2024 / Business Wire / Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that an encore presentation of results from the pivotal, Phase 3 IMPALA-2 trial will be presented at the British Thoracic Society (BTS) Winter Meeting, taking place November 27-29, 2024, in London, England. BTS Platform Presentation Details... Read More

LANGHORNE, Pa. / Nov 13, 2024 / Business Wire / Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of its management team will be attending the below listed upcoming healthcare conferences and participating in fireside chats. Jefferies London Healthcare Conference, November 19-21, 2024 Fireside Chat: November 20th, 1:00pm... Read More

Recently Completed Pre-BLA Meeting with FDA for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Company Plans to Initiate Biologics License Application (BLA) Rolling Submission by End of Year Updates Guidance on MOLBREEVI BLA Submission Completion Date to End of 1Q 2025 from 1H 2025 – Intends to Request Priority Review Expects to Submit MOLBREEVI Marketing Authorization Application (MAA) to the European... Read More

LANGHORNE, Pa. / Nov 04, 2024 / Business Wire / Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Guggenheim Inaugural Healthcare Conference on November 12, 2024 at 10:00am PT/1:00pm ET. A live webcast and subsequent replay of the fireside chat will be available on... Read More

LANGHORNE, Pa. / Oct 22, 2024 / Business Wire / Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that a new episode of The Balancing Act ® , sponsored by Savara and featuring autoimmune Pulmonary Alveolar Proteinosis (aPAP), is airing on Lifetime TV’s Behind the Mystery™ a recurring series on The Balancing Act ® television show devoted to... Read More

LANGHORNE, Pa. / Oct 18, 2024 / Business Wire / Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to four new employees. On October 17, 2024, the Compensation Committee of Savara's Board of Directors granted the inducement awards to four new employees who recently joined the Company. The inducement awards consist of... Read More

Company-Sponsored Industry Symposium to be Held at the CHEST 2024 Annual Meeting LANGHORNE, Pa. / Oct 01, 2024 / Business Wire / Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of an abstract for poster presentation at the CHEST 2024 Annual Meeting, taking place October 6-9 in Boston. The Company is also sponsoring an Industry... Read More

LANGHORNE, Pa. / Sep 27, 2024 / Business Wire / Savara Inc . (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee. On September 25, 2024, Savara's Board of Directors granted the inducement awards to Braden Parker, who joined the Company as Chief Commercial Officer on September 24, 2024. The inducement awards consist... Read More

Program Enables Physicians to Request Molgramostim for Eligible Patients in Select Geographies Where the Product is Not Commercially Available and in Compliance with Local Regulatory Requirements LANGHORNE, Pa. / Sep 27, 2024 / Business Wire / Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the Savara Early Access Program, a... Read More

Mr. Parker has More Than 25 Years of Commercial Leadership Experience and has Launched Multiple Rare Disease Products LANGHORNE, Pa. / Sep 24, 2024 / Business Wire / Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the appointment of Braden Parker as Chief Commercial Officer, effective immediately. Mr. Parker is a seasoned global... Read More

LANGHORNE, Pa. / Sep 23, 2024 / Business Wire / Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, will host an analyst and investor webinar on September 30, 2024 from 8:30-9:30 a.m. ET to present data from the Phase 3 IMPALA-2 clinical trial of molgramostim inhalation solution (molgramostim) in autoimmune Pulmonary Alveolar Proteinosis (aPAP) and... Read More

Mean Change From Baseline in Disease Severity Score (DSS) Showed Significant Improvement with Molgramostim Compared with Placebo at Weeks 24 and 48 Responder Analysis Results for Percent Predicted Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO%) Showed Significantly Higher Proportions of Molgramostim Responders Compared with Placebo at Weeks 24 and 48 Responder Analysis Results for St. George’s Respiratory... Read More

LANGHORNE, Pa. / Sep 06, 2024 / Business Wire / Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee. On September 5, 2024, the Compensation Committee of Savara's Board of Directors granted the inducement awards to a new employee who recently joined the Company. The inducement awards consist of options to... Read More

LANGHORNE, Pa. / Sep 03, 2024 / Business Wire / Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 10, 2024 at 10:00am ET/7:00am PT. A live webcast of the presentation will be available on Savara’s website at... Read More

AUSTIN, Texas / Aug 16, 2024 / Business Wire / Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee. On August 15, 2024, the Compensation Committee of Savara's Board of Directors granted the inducement awards to a new employee who recently joined the Company. The inducement awards consist of options to... Read More

Company-Sponsored Industry Symposium To Be Held at the ERS Congress LANGHORNE, Pa. / Aug 15, 2024 / Business Wire / Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of an abstract for poster presentation at the European Respiratory Society (ERS) Congress 2024, taking place September 7-11, 2024, in Vienna, Austria. The... Read More

LANGHORNE, Pa. / Aug 12, 2024 / Business Wire / Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the second quarter ending June 30, 2024 and provided a business update. Recent Business Highlights Reported positive top line results from IMPALA-2, a pivotal, Phase 3 clinical trial of molgramostim nebulizer solution... Read More

LANGHORNE, Pa. / Jun 28, 2024 / Business Wire / Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the pricing of an underwritten offering of 26,246,720 shares of its common stock at a price of $3.81 per share before deducting underwriting discounts and commissions, for total gross proceeds of approximately $100.0 million. All of the securities to be... Read More

Statistically Significant Improvement in Percent Predicted Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) Versus Placebo at Week 24 (Primary Endpoint) and Week 48 (Secondary Endpoint) Statistically Significant Improvement in St. George’s Respiratory Questionnaire (SGRQ) Total Score at Week 24 (Secondary Endpoint) 97% of Patients Completed Double-Blind Treatment Through Week 48 with No Trial Drug Related Adverse... Read More

Conference Call to Take Place Tomorrow, Wednesday, June 26, 2024, at 8:00am ET LANGHORNE, Pa. / Jun 25, 2024 / Business Wire / Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it will host a conference call and webcast tomorrow, Wednesday, June 26, 2024, at 8:00am ET to discuss top line results from the pivotal, Phase 3 IMPALA-2... Read More

LANGHORNE, Pa. / May 29, 2024 / Business Wire / Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5, 2024 at 7:00am PT/10:00am ET. A live webcast of the fireside chat will be available on Savara’s website at... Read More

Savara’s Partner, Trillium Health LLC, Presented Data on the Laboratory Blood Test for Diagnosing aPAP LANGHORNE, Pa. / May 19, 2024 / Business Wire / Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the American Thoracic Society (ATS) 2024 International Conference that is taking place May 17-22, 2024, in San Diego, CA. Savara’s... Read More

AUSTIN, Texas / May 16, 2024 / Business Wire / Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee. On May 14, 2024, the Compensation Committee of Savara's Board of Directors granted the inducement awards to a new employee who recently joined the Company. The inducement awards consist of options to... Read More

Pivotal Phase 3 IMPALA-2 Trial Remains On-track, Top Line Results Expected by End of 2Q 2024 48-week placebo-controlled trial is evaluating molgramostim nebulizer solution (molgramostim), a novel inhaled biologic, for the treatment of autoimmune Pulmonary Alveolar Proteinosis (aPAP), a rare lung disease Pending Results from the IMPALA-2 Trial, a Biologics License Application (BLA) Filing is Anticipated in 1H 2025 With ~$143M... Read More

LANGHORNE, Pa. / May 07, 2024 / Business Wire / Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Citizens JMP Life Science Conference on May 14, 2024 at 6:00am PT/9:00am ET. A live webcast of the fireside chat will be available on Savara’s website at... Read More

Savara’s Partner, Trillium Health LLC, to Present Data on the Laboratory Blood Test for Diagnosing aPAP Company to Host Industry Theater on Pulmonary Alveolar Proteinosis (PAP) with Two World-Renowned Experts LANGHORNE, Pa. / Apr 08, 2024 / Business Wire / Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of two abstracts... Read More

AUSTIN, Texas / Mar 22, 2024 / Business Wire / Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees. On March 21, 2024, Savara's Board of Directors granted the inducement awards to two new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of... Read More

Remains On-Track to Report Top Line Data from the Pivotal Phase 3 IMPALA-2 Trial by End of 2Q 2024 48-week placebo-controlled trial is evaluating molgramostim nebulizer solution (molgramostim), a novel inhaled biologic, for the treatment of autoimmune Pulmonary Alveolar Proteinosis (aPAP), a rare lung disease Anticipate Filing Biologics License Application (BLA) in 1H 2025, Pending Outcome of IMPALA-2 Trial With ~$162M in... Read More

LANGHORNE, Pa. / Mar 06, 2024 / Business Wire / Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference on March 14, 2024 at 5:00am PT/8:00am ET. A live webcast of the fireside chat will be available on Savara’s website at... Read More

AUSTIN, Texas / Feb 02, 2024 / Business Wire / Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee. On January 31, 2024, the Compensation Committee of Savara's Board of Directors granted the inducement awards to a new employee who recently joined the Company. The inducement awards consist of options to... Read More

Guggenheim 6th Annual Biotechnology Conference Oppenheimer 34th Annual Healthcare Life Sciences Conference LANGHORNE, Pa. / Jan 31, 2024 / Business Wire / Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will be participating at the following investor healthcare conferences: Guggenheim 6th Annual Biotechnology Conference... Read More

The simple, no-cost, and noninvasive test is now available to physicians in the U.S. Company launches campaign in the U.S. to raise awareness of the rare autoimmune lung disease and need for early testing LANGHORNE, Pa. / Dec 21, 2023 / Business Wire / Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, recently launched aPAP ClearPath™, a new serum-based... Read More

LANGHORNE, Pa. / Dec 20, 2023 / Business Wire / Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the company was added to the NASDAQ Biotech Index (Nasdaq: NBI), effective prior to market open on Monday, December 18, 2023. The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock... Read More

AUSTIN, Texas / Dec 15, 2023 / Business Wire / Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee. On December 11, 2023, the Compensation Committee of Savara's Board of Directors granted the inducement awards to a new employee who recently joined the Company. The inducement awards consist of options to... Read More

LANGHORNE, Pa. / Nov 21, 2023 / Business Wire / Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on November 28, 2023 at 1:00pm PT/4:00pm ET. A live webcast of the fireside chat will be available on Savara’s website at... Read More

Top Line Data from the Pivotal Phase 3 IMPALA-2 Trial Remains On-Track to Read Out by End of 2Q 2024 48-week placebo-controlled trial is evaluating molgramostim nebulizer solution (molgramostim), a novel inhaled biologic, for the treatment of autoimmune Pulmonary Alveolar Proteinosis (aPAP), a rare lung disease Company Expects to Launch an aPAP Antibody Blood Test and Disease Awareness Campaign in the U.S. by End of Year... Read More

LANGHORNE, Pa. / Nov 08, 2023 / Business Wire / Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Jefferies London Healthcare Conference on November 15, 2023 at 12:00pm GMT/7:00am EST. A live webcast of the fireside chat will be available on Savara’s website at... Read More

AUSTIN, Texas / Oct 06, 2023 / Business Wire / Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to three new employees. On October 3, 2023, the Compensation Committee of Savara's Board of Directors granted the inducement awards to three new employees who recently joined the Company. The inducement awards consist of... Read More

LANGHORNE, Pa. / Sep 05, 2023 / Business Wire / Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the H.C. Wainwright 25 th Annual Global Investment Conference on September 12, 2023 at 3:30pm ET/12:30pm PT. A live webcast of the presentation will be available on Savara’s website at... Read More

Fully Enrolled Pivotal Phase 3 IMPALA-2 Trial Remains On-Track to Report Top Line Data by End of 2Q 2024 — 48-week placebo-controlled trial is evaluating molgramostim nebulizer solution (molgramostim), a novel inhaled biologic, for the treatment of autoimmune Pulmonary Alveolar Proteinosis (aPAP), a rare lung disease ~$105M in Cash and Cash Equivalents at the End of 2Q 2023 Further Strengthened Balance Sheet in July with an... Read More

AUSTIN, Texas / Aug 04, 2023 / Business Wire / Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to three new employees. On August 3, 2023, the Compensation Committee of Savara's Board of Directors granted the inducement awards to three new employees who recently joined the Company. The inducement awards consist of... Read More

LANGHORNE, Pa. / Jul 13, 2023 / Business Wire / Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the pricing of an underwritten offering of 21,000,000 shares of its common stock at a price of $3.00 per share and, in lieu of common stock to certain investors that so choose, 5,666,667 pre-funded warrants to purchase common stock at a price of $2.999... Read More

AUSTIN, Texas / Jun 26, 2023 / Business Wire / Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has been added to the U.S. broad-market Russell 3000 ® Index at the conclusion of the Russell indexes annual reconstitution, effective upon the U.S. market open on Monday, June 26, 2023. Annual Russell indexes reconstitution captures the 4,000... Read More

Target Enrollment was 160 Patients, IMPALA-2 Enrolled 164 Patients Company Remains On-Track to Report Top Line Data by End of 2Q 2024 AUSTIN, Texas / Jun 26, 2023 / Business Wire / Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that enrollment has been completed for the pivotal Phase 3 IMPALA-2 trial. A total of 164 patients were randomized. Target... Read More

AUSTIN, Texas / Jun 02, 2023 / Business Wire / Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Jefferies Healthcare Conference on June 9, 2023 at 10:30 am ET/7:30 am PT. A live webcast of the fireside chat will be available on Savara’s website at... Read More

Pivotal Phase 3 IMPALA-2 Trial Remains On-Track Company expects trial to be fully enrolled in June 2023, on-track to report top line data by end of 2Q 2024 48-week placebo-controlled trial is evaluating molgramostim nebulizer solution (molgramostim), a novel inhaled biologic, for the treatment of autoimmune Pulmonary Alveolar Proteinosis (aPAP), a rare lung disease Company Ends Quarter with ~$115M, Believes it is... Read More

AUSTIN, Texas / May 05, 2023 / Business Wire / Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees. On May 3, 2023, the Compensation Committee of Savara's Board of Directors granted the inducement awards to two new employees who recently joined the Company. The inducement awards consist of options to... Read More

AUSTIN, Texas / Mar 31, 2023 / Business Wire / Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees. On March 29, 2023, the Compensation Committee of Savara's Board of Directors granted the inducement awards to two new employees who recently joined the Company. The inducement awards consist of options... Read More

Pivotal Phase 3 IMPALA-2 Trial Remains On-Track with Top Line Data Expected End of 2Q 2024 IMPALA-2 is evaluating molgramostim nebulizer solution (molgramostim), a novel inhaled biologic, for the treatment of autoimmune Pulmonary Alveolar Proteinosis (aPAP), a rare lung disease IMPALA-2 Trial Continues, Unmodified, Following Positive Review from Independent Data Monitoring Committee (DMC) DMC assessed the safety and... Read More

AUSTIN, Texas / Mar 06, 2023 / Business Wire / Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the Oppenheimer 33rd Annual Healthcare Conference on March 13, 2023 at 1:20pm ET. A live webcast of the presentation will be available on Savara’s website at www.savarapharma.com/investors/events-presentations/ and... Read More

AUSTIN, Texas / Feb 28, 2023 / Business Wire / Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee. On February 24, 2023, Savara's Board of Directors granted the inducement award to Robert M. Lutz, who joined the Company as Chief Operating Officer on February 13, 2023. The inducement award consists of... Read More

AUSTIN, Texas / Feb 14, 2023 / Business Wire / Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the appointments of two pharmaceutical industry veterans to its executive leadership team. Rob Lutz has been appointed Chief Operating Officer, effectively immediately. Scott Wilhoit was appointed Executive Vice President, Global Commercial, effective... Read More

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees. On January 17, 2023, the Compensation Committee of Savara's Board of Directors granted the inducement awards to two new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 195,000 shares of... Read More